Sep 10, 2007

Stories You Might Like Meet the fact-checkers trying to clean up Facebook Meet the fact-checkers trying to clean up Facebook One problem with fake news? It really, really works (Replay) One problem with fake news? It really, really works 01/08/2018: How China is creating false demand for electric cars Marketplace Morning Report for Wednesday, March […]

Segments From this episode

Toy industry tries to get the lead out

Sep 10, 2007
U.S. and Chinese regulators are expected to adopt new standards to prevent products containing lead paint from entering the United States. But, as Amy Scott reports, with the holiday shopping season approaching, the toy industry is taking matters into its own hands.

An easy-to-read label is hard to find

Sep 10, 2007
FDA officials are debating whether changes in food labels might help consumers make healthy choices. Helen Palmer reports there are plenty of ideas but not much consensus.

Troop cuts could mean contractor surge

Sep 10, 2007
General David Petraeus told Congress today that he believes the United States can reduce its presence in Iraq to pre-surge levels by next summer. Steve Henn reports that American defense contractors see that as a business opportunity.

KKR makes offer to reassure its lenders

Sep 10, 2007
The private-equity firm Kohlberg Kravis Roberts has agreed to conditions on loans it's taking out to buy the credit card processing firm First Data. Bob Moon explains.

Syria transfers to modern banking

Sep 10, 2007
Imagine a place with no loans, no checks and no credit cards. That was the Syrian economy just a couple of years ago. But now the government is modernizing the financial system, with private banks leading the way. Jennifer Glasse reports.

Watch out for those library fines

Sep 10, 2007
With Wall Street still caught up in its liquidity crisis, it's probably a good time for those with squeaky clean credit records to keep them that way. Commentator Susan Lee says you'd be surprised how much even the littlest things can hurt.

Leading through a period of trial

Sep 10, 2007
The biotechnology company Amgen produces two drugs for anemia that have earned the company billions of dollars. But new findings could result in strong warnings being placed on the drugs. Amgen CEO Kevin Sharer talked about his company's situation with Kai Ryssdal.

Half-priced hoodies! 😲 

This weekend only, get our new Marketplace zip up hoodie when you donate $8/month instead of $16/month. Don’t wait this offer ends at midnight Sunday!